Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Olaparib Approved in China for Frontline Maintenance in Ovarian Cancer

December 5th 2019

China’s National Medical Products Administration has granted marketing authorization for olaparib as a first-line maintenance treatment for adult patients with newly diagnosed advanced germline or somatic BRCA-mutated epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to frontline platinum-based chemotherapy.

Dr. Crafton on Secondary Surgical Cytoreduction in Ovarian Cancer

December 4th 2019

Sarah Crafton, MD, gynecologic oncologist, Allegheny Health Network, discusses secondary surgical cytoreduction in recurrent ovarian cancer.

UK Expands Olaparib Maintenance Indication in Ovarian Cancer

December 3rd 2019

The UK’s National Institute for Health and Care Excellence has approved olaparib for the maintenance treatment of adult patients with relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer whose disease responded to platinum-based chemotherapy and harbor BRCA1/2 mutations.

Recent Data Muddle Role of Secondary Surgery in Recurrent Ovarian Cancer

December 3rd 2019

Sarah Crafton, MD, discusses the role of secondary surgical cytoreduction in recurrent ovarian cancer.

Dr. Crafton on Optimizing Treatment Selection in Recurrent Ovarian Cancer

November 28th 2019

Sarah Crafton, MD, gynecologic oncologist, Allegheny Health Network, discusses optimizing treatment selection in recurrent ovarian cancer.

Dr. Salani Discusses Neoadjuvant Chemotherapy Versus Primary Debulking Surgery in Ovarian Cancer

November 22nd 2019

Ritu Salani, MD, discusses considerations for neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer.

Combos Could Unlock Major Immunotherapy Benefits in Ovarian Cancer

November 22nd 2019

John Hays, MD, PhD, discusses ongoing research with immunotherapy in ovarian cancer, challenges with determining predictive biomarkers of response, and promising emerging modalities.

Expert Shares Insight on Evolution of Ovarian Cancer Therapeutics

November 21st 2019

Larry J. Copeland, MD, discusses how therapy for patients with ovarian cancer has evolved in recent years.

Dr. Copeland on the Etiology of Ovarian Cancer

November 21st 2019

Larry J. Copeland, MD, discusses the etiology of ovarian cancer.

Individualized Approach Imperative in Frontline Ovarian Cancer

November 20th 2019

Ritu Salani, MD, discusses the evolution of up-front chemotherapy, as well as the roles of primary debulking surgery and neoadjuvant chemotherapy in ovarian cancer.

O'Malley Highlights Pivotal Trials in Ovarian Cancer

November 19th 2019

David O’Malley, MD, discusses clinical trials in ovarian cancer and others under investigation.

Genetic Testing Is Suggested First Step Upon Ovarian Cancer Diagnosis

November 18th 2019

Leigha Senter, MS, LGC, discusses the current state of genetic testing for patients with ovarian cancer.

Secondary Cytoreduction Does Not Improve Survival in Recurrent Ovarian Cancer

November 15th 2019

Secondary cytoreduction followed by chemotherapy was not found to improve overall survival compared with chemotherapy alone in patients with platinum-sensitive recurrent ovarian cancer.

Dr. Cosgrove on Selecting a PARP Inhibitor for Maintenance Therapy in Ovarian Cancer

November 12th 2019

Casey M. Cosgrove, MD, discusses factors to consider when selecting a PARP inhibitor as maintenance therapy in advanced ovarian cancer.

Potential of Genetic Testing Beyond BRCA1/2 in Ovarian Cancer

November 9th 2019

Leigha Senter, MS, LGC, discusses the implications of identifying genes beyond BRCA1/2 in women with ovarian cancer.

Dr. Backes on Treatment Selection With PARP Inhibitors in Ovarian Cancer

November 8th 2019

Floor J. Backes, MD, associate professor, Division of Gynecologic Oncology, The Ohio State University Comprehensive Cancer Center, discusses treatment selection with PARP inhibitors in ovarian cancer.

Efforts Continue to Perfect PARPi Use in Ovarian Cancer

November 8th 2019

As PARP inhibitors have now moved into the frontline maintenance setting in ovarian cancer, researchers are now seeking to even further capitalize on use of these agents, including indications in treatment-naïve patients.

Dr. Fowler on Considerations for Cytoreductive Surgery in Ovarian Cancer

November 7th 2019

Jeffrey M. Fowler, MD, discusses factors used to determine whether a patient with advanced ovarian cancer is eligible for primary cytoreductive surgery.

Dr. O'Malley on Toxicity Profiles of PARP Inhibitors in Ovarian Cancer

November 5th 2019

David O’Malley, MD, discusses the toxicities associated with PARP inhibitors in ovarian cancer.

Experts Provide Insight on Aspects of Cancer Care That Are Not as Widespread in Community Practice

November 1st 2019

OncLive interviewed experts at the State of the Science Summits™ in October 2019 on what they wish more people knew in community practice that is not yet widespread.